Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are currently receiving, planning to receive, or have recently finished chemoradiation treatment using proton therapy for esophageal cancer (Group 1A).
- You are currently receiving, planning to receive, or have recently finished chemoradiation treatment using a type of radiation called IMRT for esophageal cancer (Group 1B).
- You are currently receiving, planning to receive, or have recently finished proton therapy as a main treatment for liver cancer that cannot be surgically removed (Group 2A).
- You are currently receiving, planning to receive, or have recently finished IMRT as a main treatment for liver cancer that cannot be surgically removed (Group 2B).
- You are a healthy individual matched by age and gender to one of the patient groups above (Group 3).
- You are over 18 years old.
- You are able to understand and are willing to sign a consent form agreeing to take part.
- People of all genders, races, and nationalities are welcome to apply.
Who may not be able to join:
- You have a weakened immune system due to an uncontrolled condition such as HIV or a similar immune disorder, or you are currently or have previously taken medication that suppresses the immune system — however, people with HIV who are on effective treatment and have had an undetectable viral load within the last 6 months may still be eligible.
- You have received or are currently receiving a treatment called intravenous immunoglobulin (IVIG) within the three months before joining or during the study.
- You have a mental health condition or personal circumstances that would make it difficult to follow the study requirements (confirm with trial site).
- You have received a pneumococcal vaccination (a vaccine against a type of bacterial infection) within the last 5 years.
- You have a severe allergic reaction to any ingredient in the vaccine being used in this study (confirm with trial site for full list of vaccine components).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Steven H Lin, MD, M.D. Anderson Cancer Center
Phone: (713) 563-8490
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Impact of grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.